Pentoxifylline gains attention as potential adjunct for diabetic kidney disease

Researchers explore whether the older anti-inflammatory drug pentoxifylline could help slow the progression of diabetic kidney disease, amid limited but promising evidence for its broader biological effects.

Pentoxifylline, an older anti-inflammatory drug, is drawing renewed attention as researchers search for additional ways to slow diabetic kidney disease, a condition that remains a leading cause of kidney failure worldwide. In an interview with AJKDBlog, kidney specialist David Leehey discussed a recent mini review in the American Journal of Kidney Diseases examining whether the drug could have a place alongside current treatment.

The review, by Leehey and Rajiv Agarwal, argues that there is still an unmet need even after the expansion of kidney-protective therapies in recent years. For many years, renin-angiotensin-aldosterone system blockade was the only targeted drug approach shown to reduce progression to end-stage kidney disease in diabetic kidney disease. Pentoxifylline, which is not a diabetes drug and is better known as a non-specific phosphodiesterase inhibitor, has been studied for its antiproteinuric and anti-inflammatory effects.

Evidence to date is encouraging but not definitive. A Cochrane review of 17 randomised trials involving 991 participants found that pentoxifylline reduced serum creatinine, albuminuria and overt proteinuria versus placebo, but did not improve creatinine clearance. A separate meta-analysis also suggested a reduction in proteinuria, while other studies have pointed to reductions in inflammatory markers. Even so, the Cochrane authors said the evidence remains too limited to support firm recommendations.

Researchers say the drug’s appeal lies partly in its broader biologic effects. According to a review highlighted by Nature Index, pentoxifylline may help by dampening inflammation, improving renal blood flow and limiting fibrotic signalling, with some emerging work also pointing to possible effects on the Klotho axis, a pathway linked to kidney and vascular health. That has led some authors to describe the drug as a potentially low-cost complement to standard blood-pressure and glucose control rather than a replacement for established care.

For now, pentoxifylline remains a candidate rather than a proven therapy. The key question, as Leehey noted in the AJKDBlog interview, is whether larger, better-designed trials can show that its signals in smaller studies translate into meaningful long-term kidney protection.